Do novel antipsychotics have similar pharmacologial characteristics? A review of the evidence

Neuropsychopharmacology

Volumn 18, Issue 2, 1998, Pages 63-101

  Arnt, J ^a   Skarsfeldt, T ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Animal models; Anxiety; Clozapine; Cognition; Depression; Extrapyramidal side effects; Haloperidol; Novel antipsychotic drugs; Receptor profiles

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPEROZIDE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR; FLUPERLAPINE; FLUPHENAZINE; HALOPERIDOL; ISOREMOXIPRIDE; NEUROLEPTIC AGENT; NEUROTENSIN; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; PERGOLIDE; PROMETHAZINE; QUETIAPINE; RECEPTOR SUBTYPE; REMOXIPRIDE; RISPERIDONE; RITANSERIN; SCOPOLAMINE; SERTINDOLE; ZIPRASIDONE;

ANXIETY; BEHAVIOR; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS;

EID: 0032007608     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(97)00112-7     Document Type: Review

References (325)

1. Aghajanian GK (1978): Feedback regulation of central monoaminergic neurons: evidence from single cell recording studies. In Youdin MBH, Lovenberg W, Sharman DF, Lagnado JR (eds), Essays in Neurochemistry and Neuropharmacology. New York, John Wiley & Sons, pp 1-228
2. Ames D, Wirshing WC, Marshall BD, Green MF, McGurk SR, Mintz J, Marder SR (1997): Risperidone vs. haloperidol in treatment resistant schizophrenia. Schizophr Res 24:193
3. Amit Z, Smith BR (1991): Remoxipride, a specific D2 dopamine antagonist: An examination of its self-administration liability and its effects on d-amphetamine self-administration. Pharmacol Biochem Behav 41:259-261
4. Arnt J, Christensen AV, Hyttel J (1981): Differential reversal by scopolamine of effects of neuroleptics in rats. Relevance for evaluation of therapeutic and extrapyramidal side-effect potential. Neuropharmacology 20:1331-1334
5. Arnt J (1982): Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 51:321-329
6. Arnt J, Hyttel J, Bach-Lauritzen T (1986): Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol Toxicol 59:319-324
7. Arnt J (1987): Behavioral studies of dopamine receptors: Evidence for regional selectivity and receptor multiplicity. In Creese I, Fraser CM (eds), Structure and Function of Dopamine Receptors. New York, Alan R. Liss, pp 199-231
8. Arnt J, Bøgesø KP, Boeck V, Christensen AV, Dragsted N, Hyttel J, Skarsfeldt T (1989): In vivo pharmacology of irindalone, a 5-HT2 receptor antagonist with predominant peripheral effects. Drug Dev Res 16:59-70
9. Arnt J (1992): Sertindole and several antipsychotic drugs differentially inhibit the discriminative stimulus effects of amphetamine, LSD and St 587 in rats. Behav Pharmacol 3:11-18
10. Arnt J (1995): Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur J Pharmacol 283:55-62
11. Arnt J (1996): Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system? Psychopharmacology 124:117-125
12. Arnt J, Christensen AV (1981): Differential reversal by scopolamine and THIP of the antistereotypic and cataleptic effects of neuroleptics. Eur J Pharmacol 69:107-111
13. Arnt J, Hyttel J (1986): Inhibition of SK & F 38393 - and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinities in vitro. J Neural Transm 67:225-240
14. Arolfo MP, Brioni JD (1991): Diazepam impairs place learning in the Morris water maze. Behav Neural Biol 55:131-136
15. Ashby CR, Wang RY (1996): Pharmacological actions of the atypical antipsychotic drug clozapine - a review. Synapse 24:349-394
16. Bakshi VP, Swerdlow NR, Geyer MA (1994): Clozapine antagonizes, phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 271:787-794
17. Bakshi VP, Geyer MA (1995): Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122:198-201
18. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992): Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 160:12-16
19. Baldessarini RJ, Frankenburg FR (1991): Drug therapy-Clozapine - A novel antipsychotic agent. N Engl J Med 324:746-754
20. Bean AJ, Roth RH (1991): Effects of haloperidol administration on in vivo extracellular dopamine in striatum and prefrontal cortex after partial dopamine lesions. Brain Res 549:155-158
21. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, and The Olanzapine HGAD Study Group (1996a): Olanzapine versus placebo-Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124:159-167
22. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, and The Olanzapine HGAD Study Group (1996b): Olanzapine versus placebo and haloperidol - Acute phase results of the north american double-blind olanzapine trial. Neuropsychopharmacology 14:111-123
23. Beatty WW, Rush JR (1983): Spatial working memory in rats: Effects of monoaminergic antagonists. Pharmacol Biochem Behav 18:7-12
24. Bench CJ, Lammertsma AA, Grasby PM, Dolan RJ, Warrington SJ, Boyce M, Gunn KP, Brannick LY, Frackowiak RSJ (1996): The time course of binding to striatal dopamine D-2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology 124:141-147
25. Bischoff S, Christen P, Vassout A (1988): Blockade of hippocampal dopamine (DA) receptors: A tool for antipsychotics with low extrapyramidal side effects. Prog Neuropsychopharmacol Biol Psychiatry 12:455-467
26. Blanc G, Trovero F, Vezina P, Hervé D, Godeheu A-M, Glowinski J, Tassin J-P (1994): Blockade of prefrontocortical alphal-adrenergic receptors prevents locomotor hyperactivity induced by subcortical D-amphetamine injection. Eur J Neurosci 6:293-298
27. Blin O, Azorin JM, Bouhours P (1996): Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 16:38-44
28. Blum PS, Robisch DM (1989): Effect of haloperidol (HAL) and risperidone (RIS) on dopaminergic (DA) neurons: Change in spontaneous activity and reversal of apomorphine (APO)-induced inhibition. Soc Neurosci Abstracts 15:1000
29. Bondolfi G, Baumann P, Dufour H (1996): Treatment-resistant schizophrenia - Clinical experience with new antipsychotics. Eur Neuropsychopharmacol 6(suppl. 2):S21-S25
30. Borsini F, Nowakowska E, Samanin R (1984): Effect of repeated treatment with desipramine in the behavioral "despair" test in rats: Antagonism by "atypical" but not "classical" neuroleptics or antiadrenergic drugs. Life Sci 34:1171-1176
31. Brauer LH, Goudie AJ, de Wit H (1997): Dopamine ligands and the stimulus effects of amphetamine: Animal models vs. human laboratory data. Psychopharmacology 130:2-13
32. Bristow LJ, Landon L, Saywell KL, Tricklebank MD (1995): The glycine/NMDA receptor antagonist, L-701,324 reverses isolation-induced deficits in prepulse inhibition in the rat. Psychopharmacology 118:230-232
33. Buchanan RW (1995): Clozapine - Efficacy and safety [review]. Schizophr Bull 21:579-591
34. Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973): Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity. Pharmacol Exp Ther 185: 560-571
35. Bunney BS, Aghajanian GK (1975): Antipsychotic drugs and central dopaminergic neurons: A model for predicting therapeutic efficacy and incidence of extrapyramidal side effects. In Sudilovsky A, Gershon S, Beer B (eds), Predictability in Psychopharmacology: Preclinical and Clinical Correlations. New York, Raven Press, pp 225-245
36. Bunney BS, Grace AA (1978): Acute and chronic haloperidol treatment: Comparison of effects on nigral dopaminergic cell activity. Life Sci 23:1715-1728
37. Busatto GF, Pilowsky LS, Costa DC, Ell PJ, Verhoeff NPLG, Kerwin RW (1995): Dopamine D-2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride - an I-123-IBZM single photon emission tomography (spet) study. Psychopharmacology 117:55-61
38. Busatto GF, Kerwin RW (1997): Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J Psychopharmacol 11:3-12
39. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT (1996a): Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
40. 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124:87-94
41. Carey GJ, Bergman J (1997): Discriminative-stimulus effects of clozapine in squirrel monkeys: Comparison with conventional and novel antipsychotic drugs. Psychopharmacology 132:261-269
42. Carlsson A, Lindquist M, Fuxe K, Hamberger G (1966): The effect of (+)-amphetamine on various central and peripheral catecholamine-containing neurones. J Pharm Pharmacol 18:128-130
43. 2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - Implications for psychosis. J Neural Transm 100:225-237
44. Carman J, Peuskens J, Vangeneugden A (1995): Risperidone in the treatment of negative symptoms of schizophrenia - A meta-analysis. Int Clin Psychopharmacol 10: 207-213
45. Casey DE (1993): Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in non-human primates. Psychopharmacology 112:55-59
46. Casey DE (1995): The nonhuman primate model: Focus on dopamine D2 and serotonin mechanisms. In Fog R, Gerlach J, Hemmingsen R (eds), Schizophrenia, Alfred Benzon Symposium 38. Copenhagen, Munksgaard, pp 287-297
47. Casey DE (1996a): Seroquel (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic. Expert Opinion Investigational Drugs 5:939-957
48. Casey DE (1996b): Behavioral effects of sertindole, risperidone, clozapine and haloperidol in cebus monkeys. Psychopharmacology 124:134-140
49. Casey DE (1996c): Side effect profiles of new antipsychotic agents. J Clin Psychiatry 57:40-45
50. Chambers RA, Moore J, Mcevoy JP, Levin ED (1996): Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 15:587-594
51. Chiodo LA, Bunney BS (1983): Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619
52. Chiodo LA, Bunney BS (1985): Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5:2539-2544
53. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40
54. Christensen AV (1994): Learned helplessness: An animal model of depression? In Palomo T, Archer T, Beninger R (eds), Strategies for Studying Brain Disorders. Madrid, Editorial Complutense, pp 33-53
55. Clarke PBS, Jakubovic A, Fibiger HC (1988): Anatomical analysis of the involvement of mesolimbocortical dopamine in the locomotor stimulant actions of d-amphetamine and apomorphine. Psychopharmacology 96:511-520
56. Conley RR, Tamminga CA, Beasley C (1997): Olanzapine vs. chlorpromazine in therapy-refractory schizophrenia. Schizophr Res 24:190
57. Cools AR, Prinssen EPM, Ellenbroek BA, Heeren DJ (1994): Role of olfactory tubercle and nucleus accumbens in the effects of classical and atypical neuroleptics: Search for regional specificity. In Palomo T, Archer T, Beninger R (eds), Strategies for Studying Brain Disorders. Madrid, Editorial Complutense, pp 33-53
58. Cools AR, Prinssen EPM, Ellenbroek BA (1995): The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test - Effect of risperidone, prothipendyl, org 5222, sertindole and olanzapine. Psychopharmacology 119:428-439
59. Corbett R, Hartman H, Kerman LL, Woods AT, Strupczewski JT, Helsley GC, Conway PC, Dunn RW (1993): Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 45:9-17
60. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995): Antipsychotic agents antagonize non-competitive n-methyl-d-aspartate antagonist induced behaviors. Psychopharmacology 120:67-74
61. Corbett R (1995): Clozapine but not haloperidol antagonizes an MK-801 discriminative stimulus cue. Pharmacol Biochem Behav 51:561-564
62. 3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881-894
63. Coward DM (1991): Pharmacological approaches to the development of atypical antipsychotics. Schizophr Res 1:297-305
64. Coward DM (1992): General pharmacology of clozapine. Br J Psychiatry 160:5-11
65. Cutmore THR, Beninger RJ (1990): Do neuroleptics impair learning in schizophrenic patients? Schizophr Res 3: 173-186
66. Das S, Fowler SC (1996): Similarity of clozapines and olanzapines acute effects on rats lapping behavior. Psychopharmacology 123:374-378
67. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS (1991): Mechanisms of action of atypical antipsychotic drugs - Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121-156
68. Deutch AY, Lee MC, Iadarola MJ (1992): Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3:332-341
69. Deutch A (1992): The regulation of subcortical dopamine systems by the prefrental cortex: Interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl. 36:61-89
70. Deutch AY, Duman RS (1996): The effects of antipsychotic drugs on fos protein expression in the prefrontal cortex - Cellular localization and pharmacological characterization. Neuroscience 70:377-389
71. Di Chiara G, Imperato A (1985): Rapid tolerance to neuroleptic-induced stimulation of dopamine release in freely moving rats. J Pharmacol Exp Ther 235:487-494
72. Didriksen M (1995a): The effect of risperidone on schedule-induced polydipsia. Behav Pharmacol 6:290-292
73. Didriksen M (1995b): Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm. Eur J Pharmacol 281:241-250
74. Didriksen M, Christensen AV (1994): The effects of amphetamine, phencyclidine, dopaminergic antagonists and atypical neuroleptics on schedule-induced polydipsia (SIP) are distinguishable. Behav Pharmacol 5:32-41
75. Didriksen M, Sams-Dodd F (1997): Effects of haloperidol, clozapine, and sertindole on cognitive function in rats after chronic treatment. Soc Neurosci Abstracts 23, 1932
76. DiPaola ED, Richelson E (1990): Cardiovascular effects of neurotensin and some analogs on rats. Eur J Pharmacol 175:279-283
77. Domeney AM, Arnt J, Costall B, Naylor RJ, Sánchez C, Smith AG (1994): Effect of sertindole on raised mesolimbic dopaminergic activity in the rat. Drug Dev Res 31:175-185
78. Doucet J-P, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin BJ, Chen J-S, Iadarola MJ, St-Jean M, Wigle N, Blanchet P, Grondin R, Robertson GS (1996): Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of FosB-like protein(s) in both the rodent and primate stratum. Eur J Neurosci 8:365-381
79. 2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Neuroscience 37:287-294.
80. Dunn CJ, Fitton A (1996): Sertindole. CNS Drugs 5:224-230
81. Dunn LA, Atwater GE, Kilts CD (1993): Effects of antipsychotic drugs on latent inhibition: Sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology 112:315-323
82. Dunnett SB, Evenden JL, Iversen SD (1988): Delay-dependent short-term memory deficits in aged rats. Psychopharmacology 96:174-180
83. Dworkin S, Bimle C (1989): 6-Hydroxydopamine lesions of the nucleus accumbens attenuate the discriminative stimulus effects of amphetamine. Drug Dev Res 16:435-441
84. Eitan N, Levin Y, Ben-Artzi E, Levy A, Neumann M (1992): Effects on antipsychotic drugs on memory functions in schizophrenic patients. Acta Psychiatr Scand 85:74-76
85. Ellenbroek BA, Cools AR (1990): Animal models with construct validity for schizophrenia. Behav Pharmacol 1:469-490
86. Ellenbroek BA (1991): The ethological analysis of monkeys in a social setting as an animal model for schizophrenia. In Olivier B, Mos J, Slangen J (eds), Animal Models in Psychopharmacology, Birkhäuser, Verlag, pp 265-284
87. Ellenbroek BA (1993): Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 57:1-78
88. Ellenbroek BA, Lubbers LJ, Cools AR (1996a): Activity of seroquel (ICI204,636) in animal models for atypical properties of antipsychotics - A comparison with clozapine. Neuropsychopharmacology 15:406-416
89. Ellenbroek BA, Budde S, Cools AR (1996b): Prepulse inhibition and latent inhibition - The role of dopamine in the medial prefrontal cortex. Neuroscience 75:535-542
90. Etherington R, Mittleman G, Robbins TW (1987): Comparative effect of nucleus basalis and fimbria-fornix lesions on delayed matching and alternation tests of memory. Neurosci Res Commun 1:135-143
91. Farber NB, Foster J, Duhan NL, Olney JW (1996): Olanzapine and fluperlapine mimic clozapine in preventing mk-801 neurotoxicity. Schizophr Res 21:33-37
92. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992): Positron emission tomographic analysis of central D1-dopamine and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine-Relation to extrapyramidal side effects. Arch General Psychiatry 49:538-544
93. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B (1995): Positron emission tomography studies on D-2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15:S19-S23
94. Feldon J, Weiner I (1991a): The latent inhibition model of schizophrenic attention disorder - Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 29:635-646
95. Feldon J, Weiner I (1991b): An animal model of attention deficit. In Boulton A, Baker G, Martin-Iverson M (eds), Neuromethods Vol 18. Animal Models in Psychiatry I. Totowa, NJ, The Humana Press Inc., pp 313-361
96. Fink-Jensen A, Ludvigsen TS, Korsgaard N (1995): The effect of clozapine on fos protein immunoreactivity in the rat forebrain is not mimicked by the addition of alpha(1)-adrenergic or 5HT(2) receptor blockade to haloperidol. Neurosci Lett 194:77-80
97. Fink-Jensen A, Hansen L, Hansen JB, Nielsen EB (1996): Regional differences in the effect of haloperidol and atypical neuroleptics on interstitial levels of DOPAC in the rat forebrain. J Psychopharmacology 10:119-125
98. Fink-Jensen A, Kristensen P (1994): Effects of typical and atypical neuroleptics on fos protein expression in the rat forebrain. Neurosci Lett 182:115-118
99. Fischman AJ, Bonab AA, Babich JW, Alpert NM, Rauch SL, Elmaleh DR, Shoup TM, Williams SA, Rubin RH (1996): Positron emission tomographic analysis of central 5-hydroxytryptamine(2) receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 279:939-947
100. Flynn SW, MacEwan GW, Altman S, Kopala LC, Smith GN, Honer WG (1997): A comparison of two atypical antipsychotics in treatment resistant schizophrenia. Schizophr Res 24:185
101. Fowler SC, Das S (1994): Haloperidol-induced decrements in force and duration of rats' tongue movements during licking are attenuated by concomitant anticholinergic. Pharmacol Biochem Behav 49:813-817
102. Frith CD (1984): Schizophrenia, memory and anticholinergic drugs. J Abnorm Psychol 93:339-341
103. Fulton B, Goa KL (1997): Olanzapine - A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281-298
104. Gardner EL, Walker LS, Paredes W (1993): Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: A brain stimulation study in the rat. Psychopharmacology 110:119-124
105. Gefvert O, Lindström LH, Langstrom J, Bergstrom M, Lundberg T, Yates RA, Larsson SD, Tuersley MD (1995): Timecourse for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg seroquel (ici 204,636) tid. [abstract] Proc 34th ACNP Meeting
106. Gerlach J, Peacock L (1995): New antipsychotics - The present status. Int Clin Psychopharmacol 10:39-48
107. Geyer MA, Wilkinson LS, Humby T, Robbins TW (1993): Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry 34:361-372
108. Gleason SD, Shannon HE (1997): Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129:79-84
109. Glenthøj B, Hemmingsen R (1989): Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat. Eur J Pharmacol 164:393-396
110. Goldberg TE, Gold JM (1995): Neurocognitive deficits in schizophrenia. In Hirsch SR, Weinberger DR (eds), Schizophrenia. Blackwell Science, pp 146-162
111. Goldberg TE, Weinberger DR (1996): Effects of neuroleptic medications on the cognition of patients with schizophrenia: A review of recent studies. J Clin Psychiatry 57:62-65
112. Goldstein JM, Litwin LC, Sutton EB, Malich JB (1993): Seroquel: Electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 112:293-298
113. Goldstein JM (1995): Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Expert Opinion Investigational Drugs 4:291-298
114. Goyer PF, Berridge MS, Morris ED, Semple WE, Comptontoth BA, Schulz C, Wong DF, Miraldi F, Meltzer HY (1996): Pet measurements of neuroreceptor occupancy by typical and atypical neuroleptics. J Nucl Med 37:1122-1127
115. Grace AA, Bunney BS (1986): Induction of depolarization block of haloperidol: Analysis using in vivo intracellular recording. J Pharmacol Exp Ther 238:1092-1100
116. Grace AA, Bunney BS, Moore H, Todd CL (1997): Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 20:31-37
117. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991): The neuropsychology of schizophrenia. Behav Brain Sci 14:1-84
118. Green JF, King D (1996): Cognitive functioning in schizophrenia. Effects of drug treatment. CNS Drugs 6:382-398
119. Grenhoff J, Tung C-S, Svensson TH (1988a): The excitatory amino acid antagonist kynurenate induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol Scand 134:567-568
120. Grenhoff J, Ugedo L, Svensson TH (1988b): Firing patterns of midbrain dopamine neurons: Differences between A9 and A10 cells. Acta Physiol Scand 134:127-132
121. Grenhoff J, Tung C-S, Ugedo L, Svensson TH (1990): The effects of amperizide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol 66:29-33
122. Griffon N, Pilon C, Sautel F, Schwartz JC, Sokoloff P (1996): Antipsychotics with inverse agonist activity at the dopamine d-3 receptor. J Neural Transm 103:1163-1175
123. Gully D, Jeanjean F, Poncelet M, Steinberg R (1995): Neuropharmacological profile of non-peptide neurotensin antagonists. Fundam Clinical Pharmacol 9:513-521
124. Guo N, Klitenick MA, Tham C-S, Fibiger HC (1995): Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain. Neuroscience 65:747-756
125. Gustafsson B, Christensson E (1990a): Amperozide and emotional behaviour. Pharmacol Toxicol Suppl. 1:34-39
126. Gustafsson B, Christensson E (1990b): Amperozide - A new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour. Pharmacol Toxicol Suppl. 1:12-17
127. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T, Karlsson P, Nakashima Y, Swahn CG (1995): Carbon-11-FLB 457 - A radioligand for extrastriatal d2 dopamine receptors. J Nucl Med 36:1275-1281
128. Hertel P, Nomikos GG, Iurlo M, Svensson TH (1996): Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology 124:74-86
129. Hirsch SR, Link CGG, Goldstein JM, Arvanitis LA (1996): ICI 204,636 - A new atypical antipsychotic drug. Br J Psychiatry 168:45-56
130. 2 receptors. J Pharmacol Exp Ther 263:176-284
131. Hoffman DC, Donovan H, Cassella JV (1993): The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist, MK-801. Psychopharmacology 111: 339-344
132. Hoffman DC, Donovan H (1995a): Effects of typical, atypical, and novel antipsychotic drugs on amphetamine-induced place conditioning in rats. Drug Dev Res 36:193-198
133. Hoffman DC, Donovan H (1995b): Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120: 128-133
134. Hökfelt T, Everitt BJ, Theodorsson-Nordtheim E, Goldstein M (1984): Occurrence of neurotensin-like immunoreactivity in subpopulations of hypothalamic, mesencephalic and medullary catecholamine neurons. J Comp Neurol 222:543-559
135. Hollerman JR, Grace AA (1989): Acute haloperidol administration induces depolarization block of nigral dopamine neurons in rats after partial dopamine lesions. Neurosci Lett 96:82-88
136. Hyttel J, Nielsen JB, Nowak G (1992): The acute effect of sertindole on brain neurotransmitter receptors (ex vivo radio-receptor studies). J Neural Transm 89:61-69
137. Ichikawa J, Meltzer HY (1992): Amperozide, a novel antipsychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens. J Neurochem 58:2285-2291
138. Imperato A, Di Chiara G (1987): Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. J Neurosci 5:297-306
139. Imperato A, Angelucci L (1989): The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. Psychopharmacol Bull 25:383-389
140. Inoue T, Tsuchiya K, Koyama T (1996): Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Pharmacol Biochem Behav 55:195-201
141. Invernizzi R, Morali F, Pozzi L, Samanin R (1990): Effects of acute and chronic clozapine on dopamine release and metabolism in the striatum and nucleus accumbens of conscious rats. Br J Pharmacol 100:774-778
142. Iversen SD, Howells RB, Hughes RF (1980): Behavioral consequences of long-term treatment with neuroleptic drugs. Adv Biochem Psychopharmacol 24:305-313
143. Jackson DM, Johansson C, Lindgren L-M, Bengtsson A (1994): Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav 48:465-471
144. Jackson DM, Westlind-Danielsson A (1994): Dopamine receptors: Molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 64:291-369
145. Jalenques I (1996): Drug-resistant schizophrenia - Treatment options. CNS Drugs 5:8-23
146. Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988): Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685-693
147. Johansson C, Jackson DM, Svensson L (1994): The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology 116:437-442
148. Kakigi T, Gao XM, Tamminga CA (1995): Drug-induced oral dyskinesias in rats after traditional and new neuroleptics. J Neural Transm 101:41-49
149. Kane J, Honigfeld G, Singer J, Meltzer H (1988): Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
150. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms - A PET study. Life Sci 57:PL103-PL107
151. 2 antagonism and EPS benefits - Is there a causal connection. Psychopharmacology 124:35-39
152. 1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121: 309-316
153. Kasper S, Tauscher J, Küfferle B, Heiden A, Neumeister A, Barnas C, Asenbaum S, Podreka I, Brücke T (1995): Spect D2 - Receptor imaging of typical and atypical antipsychotics. [abstract] Proc of 34th ACNP Meeting 228
154. Kawashima K, Araki H, Aihara H (1985): Effect of chronic administration of antidepressants on duration of immobility in rats forced to swim. Jpn J Pharmacol 40:199-204
155. 2a antagonist with a favorable ens safety profile. J Pharmacol Exp Ther 277:968-981
156. Kelly PH, Moore KE (1978): Mesolimbic dopamine neurons: effects of 6-hydroxydopamine-induced destruction and receptor blockade on drug-induced rotation in rats. Psychopharmacology 55:35-41
157. Kerwin R, Taylor D (1996): New antipsychotics. A review of their current status and clinical potential. CNS Drugs 6:71-82
158. Kilts CD, Anderson CM, Bissette G, Ely TD, Nemeroff CB (1988): Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. Biochem Pharmacol 37:1547-1554
159. Kimura K, Nomikos G, Svensson TH (1993): Effects of amperozide on psychostimulant-induced hyperlocomotion and dopamine release in the nucleus accumbens. Pharmacol Biochem Behav 44:27-36
160. Kinon BJ, Lieberman JA (1996): Mechanisms of action of atypical antipsychotic drugs - A critical analysis [review]. Psychopharmacology 124:2-34
161. 1a receptor agonist/dopamine D-2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats. Eur J Pharmacol 313:25-34
162. Klitenick MA, Taber MT, Fibiger HC (1996): Effects of chronic haloperidol on stress- and stimulation-induced increases in dopamine release: Tests of the depolarization block hypothesis. Neuropsychopharmacology 15: 424-428
163. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW (1996): Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 66:47-56
164. Köhler C, Radesater AC, Karlsson-Boethius G, Bryske B, Widman M (1992): Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride - A biochemical and autoradiographic analysis in the rat brain. J Neural Transm 87:49-62
165. Kufferle B, Brucke T, Topitzschratzberger A, Tauscher J, Gossler R, Vesely C, Asenbaum S, Podreka I, Kasper S (1996): Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Psychiatry Res Neuroimaging 68:23-30
166. Lahti RA, Evans DL, Stratman NC, Figur LM (1993): Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur J Pharmacol 236:483-486
167. Lahti RA, Lahti AC, Tamminga CA (1995a): D-2-family receptors in schizophrenia - Distribution and implications for treatment. Clin Neuropharmacol 18:5110-5120
168. Lahti RA, Roberts RC, Tamminga CA (1995b): D-2-family receptor distribution in human postmortem tissue - An autoradiographic study. Neuroreport 6:2505-2512
169. Lahti A, Silber C, Marck R, Bark N (1997): The action of sertindole on negative symptoms in schizophrenia. Schizophr Res 24:202
170. Levant B, Bissette G, Widerlov E, Nemeroff CB (1991): Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs. Regulatory Peptides 32:193-201
171. Levin ED (1988): Psychopharmacological effects in the radial-arm maze. Neurosci Biobehav Rev 12:169-175
172. Lewander T, Westerbergh S-E, Morrison D (1990): Clinical profile of remoxipride - A combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr Scand 82:92-98
173. Liégeois J-F, Bonaventure P, Delarge J, Damas J (1995): Antipsychotics and neuropeptides: The atypical profile of CI-943 and its relationship to neurotensin. Neurosci Biobehav Rev 19:519-531
174. Lundkvist C, Halldin C, Ginovart N, Nyberg S, Swahn CG, Carr AA, Brunner F, Farde L (1996): [C-11]MDL 100907, a radioligand for selective imaging of 5-HT2a receptors with positron emission tomography. Life Sci 58:PL187-PL192
175. Malmberg Å, Jackson DM, Eriksson A, Mohell N (1993): Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol 43:749-754
176. Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835
177. Marek GJ, Li AA, Seiden LS (1989): Evidence for involvement of 5-hydroxytryptamine-1 receptors in antidepressant-like drug effects on differential reinforcement-of-low-rate 72-second behavior. J Pharmacol Exp Ther 250:60-70
178. Marsha E, Stockton BS, Rasmussen K (1996): Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14:97-104
179. Matsubara S, Matsubara R, Kusumi I, Koyama T, Yamashita I (1993): Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo. J Pharmacol Exp Ther 265:498-508
180. Maurel-Remy S, Bervoets K, Millan MJ (1995): Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2a receptors. Eur J Pharmacol 280:R9-R11
181. McNamara RK, Skelton RW (1991): Diazepam impairs acquisition but not performance in the Morris water maze. Pharmacol Biochem Behav 30:651-658
182. Meert TF, De Haes PLAJ, Vermote PCM, Janssen PAJ (1990): Pharmacological validation of ritanserin and risperidone in the drug discrimination test procedure in the rat. Drug Dev Res 19:353-373
183. Megens AAHP, Niemegeers CJE, Awouters FHL (1992): Antipsychotic profile and side-effect liability of haloperidol, risperidone, and ocaperidone as predicted from their differential interaction with amphetamine in rats. Drug Dev Res 26:129-145
184. Megens AAHP, Awouters FHL, Schotte A, Meert TF, Dugovic C, Niemegeers CJE, Leysen JE (1994): Survey of the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 114:9-23
185. Meltzer HY, Nash JF (1991): Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587-604
186. Meltzer HY, Chai BL, Thompson PA, Yamamoto BK (1994): Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. J Pharmacol Exp Ther 268:1452-1461
187. Merchant KM, Dobie DJ, Dorsa DM (1992): Expression of the proneurotensin gene in the rat brain and its regulation by antipsychotic drugs. Ann NY Acad Sci 668:54-69
188. Merchant KM, Dorsa DM (1993): Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci USA 90: 3447-3451
189. Merchant KM, Dobie DJ, Filloux FM, Totzke M, Aravagiri M, Dorsa DM (1994): Effects of chronic haloperidol and clozapine treatment on neurotensin and c-fos mRNA in rat neostriatum. J Pharmacol Exp Ther 271:460-471
190. Merchant KM, Gill GS, Harris DW, Huff RM, Eaton MJ, Lookingland K, Lutzke BS, Mccall RB, Piercey MF, Schreur PJKD, Sethy VH, Smith MW, Svensson KA, Tang AH, Vonvoigtlander PF, Tenbrink RE (1996a): Pharmacological characterization of u-101387, a dopamine d4 receptor selective antagonist. J Pharmacol Exp Ther 279:1392-1403
191. 3 receptors. Cereb Cortex 6:561-570
192. Migler BM, Warawa EJ, Malick JB (1993): Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drug, Psychopharmacology 112:299-307
193. Mijnster MJ, Docter GJ, Voorn P (1995): Risperidone does not elevate neurotensin MRNA in rat nucleus accumbens and caudate-putamen. Neuroreport 6:2209-2212
194. Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newmantancredi A, Dacquet C, Bervoets K, Girardon S, Jacques V, Chaput C, Audinot V (1995): Functional correlates of dopamine D-3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297 .1. Activation of postsynaptic D-3, receptors mediates hypothermia, whereas blockade of D-2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275:885-898
195. Miller J (1990): Induction of c-fos mRNA expression in rat stria turn by neuroleptic drugs. J Neurochem 54:1453-1455
196. Moghaddam B, Bunney BS (1990): Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens and striatum of the rat: An in vivo microdia lysis study. Neurochemistry 54:1755-1760
197. Moghaddam R, Bunney BS (1993): Depolarization inactivation of dopamine neurons: Terminal release characteristics. Synapse 14:195-200
198. Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G (1995): A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients - A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245:45-49
199. Moore NA, Tye NC, Axton MS, Risius FC (1992): The behavioral pharmacology of olanzapine, a novel "atypical" antispychotic agent. J Pharmacol Exp Ther 262:545-551
200. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993): The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281-293
201. Moore NA, Rees G, Sanger G, Tye NC (1994): Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5:196-202
202. Moran PM, Fischer TR, Hitchcock JM, Moser PC (1996): Effects of clozapine on latent inhibition in the rat. Behav Pharmacol 7:42-48
203. Morris RGM (1984): Development of a water maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60.
204. Moser PC, Moran PM, Frank RA, Kehne JH (1995): Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2a antagonist. Behav Brain Res 73:163-167
205. Murase S, Grenhoff J, Chouvet G, Gonon FG, Svensson TH (1993): Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo. Neurosci Lett 157:53-56
206. Muscat R, Papp M, Winner P (1992): Antidepressant-like effects of dopamine agonists in an animal model of depression. Biol Psychiatry 31:937-946
207. Nanry KP, Pollard GT, Howard JL (1995): Olanzapine moderately increases conflict responding but does not produce a benzodiazepine-like cue in rat. Drug Dev Res 34:317-319
208. Nemeroff CB (1980): Neurotensin: Perchance an endogenous neuroleptic? Biol Psychiatry 15:283-302
209. Newman-Tancredi A, Chaput C, Verriele L, Millan MJ (1996): Clozapine is a partial agonist at cloned, human serotonin 5-HT1a receptors. Neuropharmacology 35: 119-121
210. Nielsen EB (1988): Cholinergic mediation of the discriminative stimulus properties of clozapine. Psychopharmacology 94:115-118
211. Nielsen EB, Jepsen SA (1985): Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. Eur J Pharmacol 111:167-176
212. Nielsen EB, Scheel-Krüger J (1986): Cueing effects of amphetamine and LSD: Elicitation by direct microinjections of the drugs into the nucleus accumbens. Eur J Pharmacol 125:85-92
213. 2 receptor is antagonized by R(-)-n-propylnorapomorphine, raclopride, and phenoxybenzamine. Neuropsychopharmacology 15:53-61
214. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994): Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115:147-156
215. Nordström AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995): D-1, D-2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration - A pet study of schizophrenic patients. Am J Psychiatry 152:1444-1449
216. Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B (1993): 5-HT2 and D2 dopamine receptor occupancy in the living human brain. Psychopharmacology 110:265-272
217. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 152:173-178
218. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16:1-7
219. O'Dell SJ, La Hoste GJ, Widmark CB, Shapiro RM, Potkin SG, Marshall JF (1990): Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6:146-153
220. Ögren SO, Hall H, Köhler C, Magnusson O, Lindblom L-O, Ängeby K, Florvall L (1984): Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol 102:459-474
221. 2 receptors. Neuroscience 61:269-283
222. Ögren SO, Archer T (1994): Effects of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile. Psychopharmacology 114:383-391
223. Olney JW, Farber NB (1995): Glutamate receptor dysfunction and schizophrenia [review]. Arch Gen Psychiatry 52: 998-1007
224. Osborne PG, O'Connor WT, Beck O, Ungerstedt U (1994): Acute versus chronic haloperidol: Relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release. Brain Res 634:20-30
225. Owens DGC (1996): Adverse effects of antipsychotic agents -Do newer agents offer advantages. Drugs 51:895-930
226. Padich RA, Mcloskey TC, Kehne JH (1996): 5-HT Modulation of auditory and visual sensorimotor gating .2. Effects of the 5-HT2a antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in wistar rats. Psychopharmacology 124:107-116
227. Papp M, Moryl E, Willner P (1996): Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 296:129-136
228. Pazos A, Cortes R, Palacios JM (1985): Quantitative autoradiographic mapping of serotonin receptors in the brain. II. Serotonin-2 receptors. Brain Res 346:231-249
229. Peuskens J (1995): Risperidone in the treatment of patients with chronic schizophrenia - A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166:712-726
230. 2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - A I-123 IBZM single photon emission tomography (spet) study. Psychopharmacology 124:148-153
231. 2-like receptors in vivo by 123 epidepride SPET. Schizophr Res 24:181
232. Pilowsky LS, Oconnell P, Davies N, Busatto GF, Costa DC, Murray RM, Ell PJ, Kerwin RW (1997b): In vivo effects on striatal dopamine d-2 receptor binding by the novel atypical antipsychotic drug sertindole - A i-123 ibzm single photon emission tomography (spet) study. Psychopharmacology 130:152-158
233. Pollard GT, Howard JL (1986): Similar effects of antidepressant and non-antidepressant drugs on behavior under an interresponse-time >72-s schedule. Psychopharmacology 89:253-258
234. Porter JH, Strong SE (1996): Discriminative stimulus control with olanzapine - Generalization to the atypical antipsychotic clozapine. Psychopharmacology 128:216-219
235. Prinssen EPM, Ellenbroek BA, Cools AR (1994): Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 262:167-170
236. Pugsley TA, Davis MD, Akunne HC, Mackenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW, Demattos SB, Corbin AE, Glase SA, Wise LD, Dijkstra D, Heffner TG (1995): Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 275:1355-1366
237. Rak IW, Arvanitis LA (1997): Overview of the efficacy of "seroquel" (quetiapine). Schizophr Res 24:199
238. Rasmussen K, Gates MR, Burger JE, Czachura JF (1997): The novel atypical antipsychotic olanzapine, but not the cck-b antagonist ly288513, blocks apomorphine-induced disruption of pre-pulse inhibition. Neurosci Lett 222:61-64
239. Rayevsky KS, Gainetdinov RR, Grekhova TV, Sotnikova TD (1995): Regulation of dopamine release and metabolism in rat striatum in vivo: Effects of dopamine receptor antagonists. Prog Neuropsychopharmacol Biol Psychiatry 19:1285-1303
240. Rigdon GC, Viik K (1991): Prepulse inhibition as a screening test for potential antipsychotics. Drug Dev Res 3:91-99
241. 1a receptor agonists block prepulse inhibition of acoustic startle reflex. J Pharmacol Exp Ther 263:486-493
242. Robertson GS, Fibiger HC (1992): Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 46:315-328
243. Robertson GS, Matsumura H, Fibiger HC (1994): Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066
244. Robertson GS, Fibiger HC (1996): Effects of olanzapine on regional c-Fos expression in rat brain. Neuropsychopharmacology 14:105-110
245. Ross CA, Pearlson GD (1996): Schizophrenia, the heteromodal association neocortex and development: potential for a neurogenetic approach. Trends Neurosci 19:171-176
246. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Jr., Shen Y, Meltzer HY, Sibley DR (1994): Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410
247. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995): D-4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365-368
248. Rowley M, Broughton HB, Collins I, Baker R, Emms F, Marwood R, Patel S, Patel S, Ragan CI, Freedman SB, Leeson PD (1996): 5-(4-chlorophenyl)-4-methyl-3-(1-(2-phenyl-ethyl)piperidin-4-yl)isoxazole - A potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem 39:1943-1945
249. Sakai K, Gao X-M, Tamminga CA (1996): Neuroleptic-induced oral dyskinesias in rats treated with olanzapine, sertindole and haloperidol. Soc Neurosci 22: Abstr. 431.15
250. Saller CF, Salama AI (1993): Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285-292
251. Sams-Dodd F (1996): Phencyclidine-induced stereotyped behaviour and social isolation in rats: A possible animal model of schizophrenia. Behav Pharmacol 7:3-23
252. Sams-Dodd F (1997): Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8:196-215
253. Sánchez C, Arnt J, Dragsted N, Hyttel J, Lembcl HL, Meier E, Skarsfeldt T (1991): Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuro leptic compound. Drug Dev Res 22:239-250
254. Sánchez C, Arnt J, Costall B, Domeney AM, Kelly E, Naylor RJ (1995): Sertindole: A limbic selective neuroleptic with potent anxiolytic effects. Drug Dev Res 34:19-29
255. Sánchez C, Arnt J (1995): Different anxiolytic-like profiles of novel antipsychotics in rodents. Soc Neurosci 21: Abstr. 827.10
256. Sanger DJ, Perrault G (1995): Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats. J Pharmacol Exp Ther 272:708-713
257. Scheel-Krüger J, Christensen AV, Arnt J (1978): Muscimol differentially facilitates stereotypy but antagonizes motility induced by dopaminergic drug: A complex GABA-dopamine interaction. Life Sci 22:75-84
258. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Vangompel P, Lesage AS, Deloore K, Leysen JE (1996a): Risperidone compared with new and reference antipsychotic drugs - In vitro and in vivo receptor binding. Psychopharmacology 124:57-73
259. 3 receptors in the rat brain - A quantitative autoradiographic study. Histochem J 28:791-799
260. Sebens JB, Koch T, ter Horst GJ, Korf J (1995): Differential fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur J Pharmacol 273:175-182
261. See RE, Ellison G (1990): Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia. Eur J Pharmacol 181:175-186
262. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, Mclean S, Guanowsky V, Howard HR, Lowe JA, Heym J (1995): Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275: 101-113
263. 4 receptors. Neuropsychopharmacology 16:93-110
264. Seeman P, Van Tol HHM (1994): Dopamine receptor pharmacology. Tips 15:264-270
265. Seiden LS, Dahms JL, Shaughnessy RA (1985): Behavioral screen for antidepressants: The effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule. Psychopharmacology 86:55-60
266. Sipes TA, Geyer MA (1994): Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 33:441-448
267. Sipes TA, Geyer MA (1995a): 8-OH-DPAT disruption of prepulse inhibition in rats: Reversal with (+)WAY 100,135 and localization of site of action. Psychopharmacology 117:41-48
268. Sipes TA, Geyer MA (1995b): DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT2a and not by 5-HT2c receptors. Behav Pharmacol 6:839-842
269. Skarsfeldt T (1992): Electrophysiological profile of a new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: Acute and repeated treatment. Synapse 10:25-33
270. Skarsfeldt T (1995): Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281:289-294
271. Skarsfeldt T (1996): Differential effect of antipsychotics on place navigation of rats in the Morris water maze - A comparative study between novel and reference antipsychotics. Psychopharmacology 124:126-133
272. Song F (1997): Risperidone in the treatment of schizophrenia: A meta-analysis of randomized controlled trials. J Psychopharmacol 11:65-71
273. Sorensen SM, Kehne JH, Fadayel GM, Humphreys TM, Ketteler HJ, Sullivan CK, Taylor VL, Schmidt CJ (1993): Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 266:684-691
274. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY (1993): Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 266:1374-1384
275. Stockton ME, Rasmussen K (1993): The electrophysiological effects of olanzapine, a novel atypical antipsychotic, on midbrain dopamine cells. Schizophr Res 15:166
276. Stockton ME, Rasmussen K (1996a): Olanzapine, a novel atypical antipsychotic, reverses D-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology 124:50-56
277. Stockton ME, Rasmussen K (1996b): Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14:97-104
278. Stowe ZN, Nemeroff CB (1991): The electrophysiological actions of neurotensin in the central nervous system. Life Sci 49:987-1002
279. 2 receptor binding study of risperidone and haloperidol. Pharmacol Biochem Behav 47:553-557
280. Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K (1995): Atypicality of several antipsychotics on the basis of in vivo dopamine-D-2 and serotonin-5HT(2) receptor occupancy. Neuropsychopharmacology 12:57-64
281. Suzuki T, Misawa M (1995): Sertindole antagonizes morphine-, cocaine-, and methamphetamine-induced place preference in the rat. Life Sci 57:1277-1284
282. Svendsen O, Arnt J, Boeck V, B¢ges¢ KP, Christensen AV, Hyttel J, Larsen J-J (1986): The neuropharmacological profile of tefludazine, a potential antipsychotic drug with dopamine and serotonin antagonistic effects. Drug Dev Res 7:35-47
283. Svensson TH, Tung C-S (1989): Local cooling of pre-frontal cortex induces pacemaker-like firing of dopamine neurons in rat ventral tegmental area in vivo. Acta Physiol Scand 136:135-136
284. Swann AC, Holgate KL, Staser JA, Silber CJ, Mack RJ (1997): Sertindole: A multi-center, 1 year, haloperidol controlled trial assessing the long-term safety, efficacy and quality of life in stable schizophrenic patients. Schizophr Res 24:203
285. Swerdlow NR, Geyer MA (1993): Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol Biochem Behav 44:741-744
286. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994a): Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139-154
287. Swerdlow NR, Zisook D, Taaid N (1994b): Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: Similarities to clozapine. Psychopharmacology 114:675-678
288. Swerdlow NR, Bakshi V, Geyer MA (1996a): Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279:1290-1299
289. Swerdlow NR, Braff DL, Hartston H, Perry W, Geyer MA (1996b): Latent inhibition in schizophrenia. Schizophr Res 20:91-103
290. Tamminga CA, Lahti AC (1996): The new generation of antipsychotic drugs. Int Clin Psychopharmacol 11:73-76
291. Todd CL, Moore H, Harden DG, Grace AA (1996): Microdialysis probe implantation into striatum disrupts haloperidol-induced DA cell depolarization block [abstract]. Soc Neurosci Abstracts 22 Abstr. 145.9
292. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997a): Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders -Results of an international collaborative trial. Am J Psychiatry 154:457-465
293. Tollefson GD, Tran PV, Hamilton SH, Kuntz AJ (1997b): Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders: a preliminary report. Schizophr Res 24:191
294. Tollefson G, Lu Y, Sanger T, Beasley C, Tran P (1997c): Olanzapine in the treatment of schizoaffective disorder. Schizophr Res 24:192
295. Tollefson GD, Sanger TM (1997): Negative symptoms - A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154:466-474
296. Uhl GR, Kuhar M, Snyder SH (1977): Neurotensin: Immunohistochemical localization in rat central nervous system. Proc Natl Acad Sci USA 74:4059-1063
297. Vahid-Ansari F, Nakabeppu Y, Robertson GS (1996): Contrasting effects of chronic clozapine, seroquel (ICI 204,636) and haloperidol administration on FosB-like immunoreactivity in the rodent forebrain. Eur J Neurosci 8:927-936
298. van Kammen DP, Mcevoy JP, Targum SD, Kardatzke D, Sebree TB, Sertindole Study Group (1996): A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124:168-175
299. Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991): Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614
300. Varty GB, Higgins GA (1995a): Reversal of a dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. Eur J Pharmacol 287:201-205
301. Varty GB, Higgins GA (1995b): Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology 122:15-26
302. Verdoux H, Magnin E, Bourgeois M (1995): Neuroleptic effects on neuropsychological test. Schizophrenia 14: 133-139
303. Wadenberg M-L, Ahlenius S (1995): Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: Enhancement of antipsychotic-like effects without catalepsy. Eur J Pharmacol 294:247-251
304. Wagstaff AJ, Bryson HM (1995): Clozapine - A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 4:370-400
305. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994): Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: Implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114:657-664
306. Wedzony K, Golembiowska K, Zazula M (1994): Differential effects of CGP 37849 AND MK-801, competitive and noncompetitive NMDA antagonists, with respect to the modulation of sensorimotor gating and dopamine outflow in the prefrental cortex of rats. Naunyn-Schmiedebergs Arch Pharmacol 350:555-562
307. Wehnert A, van der Burght M, Sloth-Nielsen M (1997): Comparing sertindole clinical data and patients across the oceans. Schizophr Res 24:203
308. Weiden P, Aquila R, Standard J (1996): Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 57:53-60
309. Weinberger DR (1988): Schizophrenia and the frontal lobe. Trends Neurosci 11:367-370
310. Weinberger DR, Lipska BK (1995): Cortical maldevelopment, anti-psychotic drugs, and schizophrenia - A search for common ground. Schizophr Res 16:87-110
311. Weiner I, Kidron R, Tarrasch R, Arnt J, Feldon J (1994): The effects of the new antipsychotic, sertindole, on latent inhibition in rats. Behav Pharmacol 5:119-124
312. Weiner I, Shadach E, Tarrasch R, Kidron R, Feldon J (1996): The latent inhibition model of schizophrenia - Further validation using the atypical neuroleptic, clozapine. Biol Psychiatry 40:834-843
313. Weiner I, Feldon J (1994): The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action: Comment on Dunn, Atwater and Kilts (Psychopharmacology 1993; 112:315-323). Psychopharmacology 116:379-380
314. Westerink BH, Kikkert RJ (1986): Effect of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. J Neurochem 46:1145-1152
315. Westphal R, Sanders-Bush E (1994): Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol Pharmacol 46:937-942
316. White FJ, Wang RY (1993): Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057
317. Wiley JL, Compton AD, Porter JH (1993): Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 45:263-267
318. Wiley JL (1994): Clozapines effects on phencyclidine-induced disruption of prepulse inhibition of the acoustic startle response. Pharmacol Biochem Behav 49:1025-1028
319. Willner P, Golembiowska K, Klimek V, Muscat R (1991): Changes in mesolimbic dopamine may explain stress-induced anhedonia. Psychobiology 19:79-84
320. Willner P, Muscat R, Papp M (1992): Chronic mild stress-induced anhedonia: A realistic animal model of depression. Neurosci Biobehav Rev 16:525-534
321. Youngren KD, Moghaddam B, Bunney BS, Roth RH (1994): Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci Lett 165:41-44
322. Zeng XP, Le F, Richelson E (1997): Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 321:349-354
323. Zhang H, Kiyatkin EA, Stein EA (1994): Behavioral and pharmacological modulation of ventral tegmental dendritic dopamine release. Brain Res 656:59-70
324. Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashin KB (1997): A controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiatry 154:782-791
325. Zorn SH, Jones SB, Ward KM, Liston DR (1994): Clozapine is a potent and selective muscarinic M(4) receptor agonist. Eur J Pharmacol-Mol Pharmacol Sect 269:R1-R2